First-line hormonal therapy for metastatic prostate cancer

Ajjai S Alva and Maha Hussain

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI:

Series: Oxford Oncology Library

First-line hormonal therapy for metastatic prostate cancer

Show Summary Details


• Androgen deprivation therapy ((ADT) gonadal suppression) is the standard first line therapy for patients with metastatic prostate cancer. This can be accomplished medically with the use of an LHRH-agonist or antagonist or by bilateral orchiectomy • The addition of an anti-androgen (short course or continuous) must be individualized taking into account symptoms, sides effects, and costs of therapy • Pending results of completed randomized trials, intermittent androgen deprivation therapy can be used but is considered experimental • Physicians managing patients should attend to the long-term toxicity from ADT, particularly effect on BMD and the metabolic syndromes • Considering the inevitability of progression in virtually all patients undergoing ADT, new treatment strategies targeting mechanisms of progression are an active area of investigation.

Chapter.  2907 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.